Enhancing Outcomes and Reducing Treatment Burden with Advanced Therapies in Neovascular AMD and DME : Episode 12

Strategies for Loading Dose Sse for Treatment-Naive and Switch Patients

February 14, 2025

By John Kitchens, MD
Richard Gale, PhD, MEd, BSc, MBChB, FRCP, FRCOphth

Opinion

Video

Panelists discuss how loading doses remain crucial for treatment-naive patients to achieve rapid disease control, while patients switching therapies may require modified approaches based on their prior treatment response and disease activity.

EP: 1.Evolution of Anti-VEGF Agents and Unmet Needs in Retinal Diseases

EP: 2.Advantages of the Molecular Structure of Aflibercept

EP: 3.Treat-and-Extend Strategy With Aflibercept

EP: 4.Assessing New Therapies for Retinal Diseases

EP: 5.Significance of the Higher Molar Dose of Aflibercept 8 mg

EP: 6.Study Design for PULSAR and PHOTON Trials for Aflibercept 8 mg

EP: 7.Patient Selection for Aflibercept 8 mg

EP: 8.Faricimab Molecular Design and Role of Ang-2

EP: 9.Outcomes with Raricimab and Choosing Between the New Therapies

EP: 10.Safety Profile of New Therapies

EP: 11.Perspectives on the Usefulness of Real-world Data

Now Viewing

EP: 12.Strategies for Loading Dose Sse for Treatment-Naive and Switch Patients

EP: 13.Impact of Durable Therapies on Patients and Clinics and Monitoring Strategies

Video content above is prompted by the following:

How strictly do you adhere to the loading dose recommendations for new therapies in treatment-naive patients with neovascular age-related macular degeneration and diabetic macular edema?
How about for patients who are switching therapies?

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!